There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) and Amicus (NASDAQ:FOLD) with bullish sentiments.
Deciphera Pharmaceuticals Inc (DCPH)
In a report released yesterday, Arlinda Lee from Canaccord Genuity maintained a Buy rating on Deciphera Pharmaceuticals Inc, with a price target of $55. The company’s shares opened today at $36.01.
Lee commented:
“We continue to expect DCC-2618 durability in GIST cohorts will be a key focus for investors. The Phase 1 is assessing DCC-2618 in 3 separate indications, GIST (cohorts for 2L, 4L, and 5L), advanced systemic mastocytosis (aSM), and glioma/ glioblastoma multiforme (GBM). In November, Deciphera initiated pivotal Invictus trial in 4L GIST and plans to start second Ph3 Intrigue 2L GIST trial by year-end. DCC-2618 has US and EU orphan designation.”
According to TipRanks.com, Lee is a 2-star analyst with an average return of 0.5% and a 41.9% success rate. Lee covers the Healthcare sector, focusing on stocks such as Eloxx Pharmaceuticals Inc, Karyopharm Therapeutics, and Aquinox Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Deciphera Pharmaceuticals Inc with a $51 average price target.
See today’s analyst top recommended stocks >>
Amicus (FOLD)
In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Amicus, with a price target of $31. The company’s shares opened today at $15.70.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 33.5% and a 56.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amicus with a $22 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
